The European Commission has approved the Menarini Group’s Orsedu (elacestrant) as a monotherapy for the treatment of postmenopausal women and men with breast cancer.
The Novo Nordisk Foundation is planning to build a €127 million ($135 million) facility in Denmark to speed up the development and manufacturing process for cell therapies for use in early clinical trials.
AGC Biologics is a global contract development manufacturing organization (CDMO) providing development and manufacturing services for protein-based biologics and advanced therapies.
A rescue medication could help reverse the effect of the most powerful synthetic opioids including fentanyl if accepted by the US Food and Drug Administration (FDA).
This week's woman in science, is Maria Pereira, who leads the Innovation Hub at TISSIUM, a Paris-based medtech startup that develops solutions for tissue reconstruction.
The UK startup Broken String Biosciences has raised a $15 million Series A round to fund the development of a DNA sequencing platform that maps off-target DNA breaks resulting from genome editing technology.
The contract development and manufacturing organization (CDMO) Fujifilm Diosynth Biotechnologies has completed a UK manufacturing facility for the production of advanced therapies including viral gene therapies, oncolytic viruses and viral vaccines for...
The big pharma company Bristol Myers Squibb (BMS) has recruited contract manufacturing and development organization (CDMO) Samsung Biologics to manufacture a commercial antibody cancer treatment until 2030.
LabGenius, a company focused on machine learning (ML) for antibody discovery, has presented key data in a poster presentation at the Single-Domain Antibodies 2023 Meeting.
Moderna has revealed that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for Spikevax, its updated COVID-19 vaccine.
Global biopharmaceutical company Takeda is working to modernize its operations in order to better serve clinical trial sites, patients and sponsor outcomes.
Vaxess Technologies, a life sciences company developing a shelf-stable vaccine patch with potential for self-application, has announced an additional $9 million in venture capital funding, with investors including RA Capital, The Engine, and GHIC, and...
Arrowhead Pharmaceuticals has spotlighted the potential of RNA interference (RNAi) therapeutic candidates in the lungs, with a clinical late breaker and multiple pre-clinical presentations at this year’s European Respiratory Society (ERS) International...
Kuano, a drug discovery company combining quantum mechanics with AI, has announced the close of its £1.8 million seed funding round, led by Mercia Ventures, and including ACF Investors, Ascension Ventures, o2h Ventures, Meltwind Advisory LLP, and other...
TherageniX, a University of Nottingham spin out pioneering a dry powder gene therapy formulation for bone graft augmentation, has been awarded a £995,000 grant from Innovate UK.
Chiesi, the biopharmaceutical and healthcare group, has announced that the National Institute for Health and Care Excellence (NICE) has recommended Elfabrio (pegunigalsidase alfa) as a treatment for Fabry disease in adults.
BioNTech and Pfizer have received a positive opinion from The Committee for Medicinal Products for Human Use (CHMP) for their updated COVID-19 vaccine, as a single dose for individuals 5 years of age and older, regardless of prior vaccination history,...
Octave Bioscience, a precision care company advancing treatments for multiple sclerosis (MS), has announced the publication of the successful clinical validation of its multiple sclerosis disease activity (MSDA) test in the peer-reviewed journal Clinical...
Huadong has been granted exclusive rights in Greater China to develop and commercialize MC2’s drug, Wynzora Cream, for the treatment of plaque psoriasis.
Intellegens, a company applying machine learning (ML) to accelerate innovation in R&D, has secured a £1.6m grant from Innovate UK, to apply ML in the emerging field of oligonucleotide therapies.
Cancer immunotherapy, more commonly known as immuno-oncology, continues to gather momentum. As a rapidly evolving field, ongoing research and advancements are coming together to expand the number of available treatments, many of which are showing incredible...
Quest Diagnostics, a provider of diagnostic information services, has announced that its AAVrh74 ELISA assay (CDx) has been granted breakthrough device designation from the U.S. Food and Drug Administration (FDA).
Optibrium, a developer of software and AI solutions for drug discovery, has acquired BioPharmics in a view to expand its 3D drug design and modelling offering.
GEDiCube is joining NVIDIA Inception, a program which guides start-ups by providing access to cutting-edge technology, technical resources, and venture capitalists.
Lytix Biopharma, a clinical stage immuno-oncology company, has completed recruitment of 20 patients in its trial evaluating LTX-315, the company’s lead drug candidate.
Synthego, a leading provider of industrialized genome editing solutions, and bit.bio, the company coding human cells for novel cures, have expanded their partnership to build a platform centered on the implementation of synthetic circuitry in cells for...
The FDA recently granted approval for Johnson & Johnson’s (J&J) Akeega, a novel first-in-class combination tablet treatment for adults with breast cancer gene (BRCA)-positive, metastatic castration-resistant prostate cancer (mCRPC).
Novartis announced today (Monday August 28) that new long-term data from its open-label trial extension demonstrated twice-yearly dosing inclisiran with statin therapy provides consistent low-density lipoprotein cholesterol (LDL-C) reduction beyond six...
Kiora Pharmaceuticals has been granted US and European patents covering local ocular delivery of the KIO-100 family of non-steroidal, anti-inflammatory small molecules.
Polpharma Biologics, a biotech company developing and manufacturing biosimilars, has announced that the U.S. Food and Drug Administration (FDA) is the first regulatory body worldwide to approve the use of Tyruko.
Kadans Science Partner is set to welcome AviadoBio to its recently completed wet lab innovation and workspace centre at 20 Water Street in Canary Wharf.
Cell and Gene Therapy Catapult, Rentschler Biopharma, and Refeyn have announced a new partnership to develop and apply ‘innovative’ process analytical technologies (PAT) to improve the process and efficiency of AAV manufacture.
A research team led by University of California, Irvine scientists has developed an ‘innovative’ method for quickly creating vast collections of chemical compounds used in drug discovery by using ribosomes, the molecules found in all cells that synthesize...
With so many advanced therapies on the horizon, the next few years are poised to be one of significant progress for patients with over 2000 cell and gene therapies in active clinical trials globally.
LEO Pharma has acquired Timber Pharmaceuticals, in a deal that will add an ‘attractive’ late stage asset to its pipeline in medical dermatology, the company said.
Janssen, a Johnson & Johnson company, has announced that its bispecific antibody has been granted approval by the European Commission (EC) for use in certain patients with relapsed or refractory multiple myeloma (RRMM).
Actimed Therapeutics Ltd will put some of its additional funding of £4.75 million ($6 million) towards its attempt to provide the world’s first cure for cancer cachexia.
Talus Bioscience, a drug discovery company developing new treatments for cancer, inflammation, and other diseases, has announced $4.3 million in non-dilutive grant funding across three new awards.
Throughout 2023, the life sciences industry has been faced with many operational issues, including supply-chain uncertainty, inflation, and talent shortages.
